Dienstag, 22. Juni 2021
Navigation öffnen
Anzeige:
Canakinumab
Canakinumab
 
JOURNAL ONKOLOGIE – STUDIE

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

Rekrutierend

NCT-Nummer:
NCT03732768

Studienbeginn:
Juni 2020

Letztes Update:
17.07.2020

Wirkstoff:
Radspherin

Indikation (Clinical Trials):
Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Carcinoma, Peritoneal Neoplasms

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 1

Sponsor:
Oncoinvent AS

Collaborator:
-

Studienleiter

Helen J Blanco, MSc
Study Director
Oncoinvent AS

Kontakt

Studienlocations
(3 von 4)

Interdisziplinäres Brustzentrum der Charité im Charité Comprehensive Cancer Center
Virchowweg 23
10117 Berlin
(Berlin)
DeutschlandNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Elena Braicu, MD
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

The maximum number of subjects enrolled in this study is 33.

The following number of subjects will be recruited in the different cohorts:

- Dose escalation cohorts (Phase 1a): 3 - 24 Subjects

- Repeated injection cohorts (Phase 1b): 3 Subjects

- Expansion cohort: 6 Subjects
 

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Able and willing to provide written informed consent and to comply with the clinical study protocol

2. Age ≥ 18 years

3. Histologically confirmed epithelial ovarian, fallopian tube and primary peritoneal carcinoma

4. Platinum sensitive recurrences of ovarian carcinoma who are eligible for debulking surgery to R0.

5. AEs recovered to at least grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy at time of first administration of Radspherin®

6. ECOG Performance Status Score of 0 - 1

7. Adequate renal function

- Creatinine ≤ 1.8 mg/dl (159 μmol/l) and

- calculated creatinine clearance using the Cockcroft-Gault formula ≥ 45 ml/min, or

- measured creatinine clearance ≥ 45 ml/min

8. Adequate hepatic function

- Serum bilirubin <1.5 x upper limit of normal (ULN)

- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN

9. Adequate bone marrow function:

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/l

- Platelets ≥ 100 x 109/l

- Haemoglobin ≥ 9 g/dL

10. Adequate coagulation tests: INR ≤ 1.5 x ULN

11. For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment

12. For females of childbearing potential who have a male partner: agreement to use two adequate methods of contraception (e.g. barrier, intrauterine device, hormonal implants, combined oral contraceptives or vasectomized partner), during the treatment period and for at least 3 months after the last dose of IMP.

Exclusion Criteria:

1. Neuroendocrine tumors, or non-epithelial ovarian cancers (e.g. germ cell tumors, Sex-cord tumors)

2. Tumors of borderline malignancy

3. Other synchronous visceral metastatic lesions, symptomatic CNS metastases. Metastatic lymph nodes are acceptable, except thoracic lymph nodes.

4. Pregnant or lactating (nursing) women

5. Active infections requiring antibiotics, and/or physician monitoring or recurrent fever >38.0 ⁰C associated with a clinical diagnosis of active infection

6. Active liver disease with positive serology for active hepatitis B, hepatitis C or known HIV

7. Administration of an investigational medicinal product within 28 days, or at least 5 times the half-life, prior to enrolment

8. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the last study treatment

9. Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cervical cancer in situ or in situ stage 1 synchronous endometrial cancer)

10. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease

11. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise the safety of the subjects or interfere with the evaluation of the safety of the IMP

12. In the Investigator's opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent

13. Treatment with bevacizumab (Avastin®) within 5 weeks prior to CRS

14. Known hypersensitivity to any of the excipients in the study drug

15. Persons who have been placed in an institution under an official or judicial order

16. Persons who are dependent on the sponsor financially must be excluded from participation

17. Persons with active SARS-CoV-2 infection must be excluded from participation

Studien-Rationale

Primary outcome:

1. Number of participants with Dose Limiting Toxicities as assessed by CTCAE v5.0. (Time Frame - 12 months):
To investigate safety and toxicity of Radspherin®

2. Maximum Tolerated Dose (MTD) (Time Frame - 21 days):
To determine the MTD of Radspherin®, among the four suggested doses 1, 2, 4 and 7 MBq, as a single intraperitoneal (IP) injection and two repeated IP injections following cytoreductive surgery (CRS)

Geprüfte Regime

  • Radspherin:
    Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Erstes bundesweites Sommertreffen junger engagierter Krebspatienten
Erstes+bundesweites+Sommertreffen+junger+engagierter+Krebspatienten
© Frantab / fotolia.com

„Danke für den gemeinsamen Spirit. Möge er uns weiter beflügeln“, so ein Feedback zum ersten Sommertreffen junger Krebspatienten in Deutschland. Frauen und Männer aus der gesamten Bundesrepublik kamen vom 29. Juni bis 1. Juli 2018 das erste Mal in Lauterbach (Hessen) zu einem gemeinsamen Kennenlernen und Austausch zusammen. Die etwa 50 Teilnehmer engagieren sich in den TREFFPUNKTEN der Deutschen Stiftung...

EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose
  • PNH: Phase-III-Studie vergleicht Faktor-B-Inhibitor Iptacopan und monoklonale Anti-C5-Antikörper